Liver Cancer | Tumor

CURE’s liver cancer page features the latest cancer news and updates on liver cancer Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in liver cancer.

Experimental Drug May Induce Effective Responses in Patients With Liver Cancer, Early Study Findings Show

June 24th 2022

Treatment with an experimental drug delivered through a minimally invasive procedure may show promise in patients with liver cancer that cannot be treated with surgery.

Balancing Scientific Rigor With Empathy in Cancer Care

June 3rd 2022

Although she has always been driven to excel, Karen Driskill's, M.S., RN, purpose became more focused after her mother-in-law passed away from intrahepatic cholangiocarcinoma in 2010.

FDA Grants Imfinzi-Chemo Combo Priority Review for Advanced Biliary Tract Cancer Treatment

May 6th 2022

The priority review means that the FDA plans to speed up its review of Imfinzi combined with chemotherapy in patients with advanced or metastatic biliary tract cancer.

Cancer Survivor to Run Boston Marathon Alongside His Organ Donor, HIV Drug Shows Promise in Treating Metastatic Colon Cancer and More

April 8th 2022

From liver cancer survivor planning to run the upcoming Boston Marathon with his organ donor to a common HIV drug showing promise in treating colorectal cancer, here’s what’s happening in the cancer space this week.

Opdivo-Yervoy Combo Treatment May Prolong Survival Without Disease Progression in Subgroup of Patients With Resectable Liver Cancer

April 5th 2022

“Combination therapy with (Opdivo) plus (Yervoy) warrants further studies in the preoperative setting for patients with resectable hepatocellular carcinoma, which could transform the role of immunotherapy from palliative treatment in the metastatic setting to curative treatment in localized disease,” the study authors wrote.

FDA to Speed Up Review of Futibatinib to Treat Certain Patients With Cholangiocarcinoma

March 31st 2022

The FDA plans to decide on whether to approve futibatinib for the treatment of patients with previously treated, locally advanced or metastatic cholangiocarcinoma that harbors a certain genetic mutation by September.

‘Today Show’ Anchor Hoda Kotb Discusses Fertility Issues Following Cancer Diagnosis, Pfizer Pulls Blood Pressure Drugs Due to Cancer Concerns and More

March 25th 2022

From Pfizer issuing a voluntary recall of three blood pressure drugs due to a high level of a cancer-causing chemical to “Today Show” co-ancho Hoda Kotb discussing her struggles with fertility after receiving a diagnosis of breast cancer, here’s what’s happening in the cancer space this week.

Cabometyx-Tecentriq Combo Fails to Improve Survival in Patients With Liver Cancer

March 15th 2022

The combination of Cabometyx and Tecentriq failed to improve overall survival in patients with advanced hepatocellular carcinoma, the most common type of primary liver cancer, compared with single-agent Tecentriq or Nexavar.

‘Majority of Patients’ With Cholangiocarcinoma Still Receive Upfront Standard of Care Despite Recent FDA Drug Approvals

March 8th 2022

Despite several FDA drug approvals over the past few years in the cholangiocarcinoma space, many patients are ineligible for these treatments as a first option, signaling a significant unmet need.

Three-Drug Combo Proves Efficacious, Safe in Unresectable Liver Cancer

February 7th 2022

Treatment with a combination of PD-1 inhibition, minimally invasive chemotherapy and Lenvima improved outcomes for patients with unresectable liver cancer compared to PD-1 inhibition and Lenvima alone.

How an Ancient Japanese Art Technique Inspired My Healing Journey From Cancer

February 3rd 2022

A woman whose husband died from cancer explains how she shattered a piece of pottery and glued it back together, to represent the cracks of her life left by her loss and how her husband remains connected to her.

New Drug Combination May Improve Outcomes in Unresectable Liver Cancer

January 27th 2022

An expert from Memorial Sloan Kettering Cancer Center in New York discusses the promising findings from a study that analyzed tremelimumab plus Imfinzi for unresectable hepatocellular carcinoma, and outlines side effects patients should discuss with their doctor.

Oral Antimetabolite After Surgery Associated With Survival Benefit in Biliary Tract Cancer

January 26th 2022

Patients with biliary tract cancer achieved a better survival outcome after receiving treatment with an oral antimetabolite following surgical resection than patients who only were treated with surgery.

Patients With Unresectable Liver Cancer May Have a ‘Promising and Tolerable’ Treatment Option With Combination Therapy

January 24th 2022

The use of a non-invasive procedure combined with Lenvima plus Tyvyt demonstrated safe and effective results in patients with liver cancer not eligible for surgical resection.

Lenvima May Offer Survival Benefit With Manageable Side Effects in Recurrent HCC After Liver Transplantation

January 23rd 2022

Researchers observed this benefit in recurrent HCC after liver transplantation, which represents a patient population often excluded from clinical trials due to potential organ rejection.

Frontline Lenvima Provided Survival Benefit for Patients With Liver Cancer

January 22nd 2022

Treating patients with liver cancer initially with Lenvima instead of the standard of care was associated with a survival benefit, according to recent research.

Minimally Invasive Procedure Combined with Lenvima and Checkpoint Blockade Shows Promise in Unresectable Liver Cancer

January 21st 2022

The use of a minimally invasive procedure — known as trans-arterial chemoembolization — plus Lenvima and a PD-1 checkpoint blockade drug proved to be safe and efficacious in patients with unresectable advanced liver cancer.

Immunotherapy Use Increased in Patients Ineligible for Cancer Trials, Highlighting the Need for More Research in Vulnerable Populations

December 28th 2021

The use of immunotherapy in patients with advanced cancers and decreased fitness levels or organ function increased from 2014 to 2019, although trials for this treatment typically exclude this population.

Top 5 Liver Cancer-Related Stories in 2021

December 22nd 2021

CURE® took a look back at our most-read liver cancer stories from this year.

Noninvasive Bridging Therapy Underutilized Versus More Invasive Options in Transplant-Eligible Hepatocellular Carcinoma

November 8th 2021

External-beam radiation, a noninvasive option for bridging therapy, may be underused compared with other liver-directed therapies and may highlight a treatment gap in this area.

Vietnam Veterans With Cholangiocarcinoma Get Help to Navigate Filing Claims With the VA in Commemoration of Veterans Day

November 5th 2021

Cholangiocarcinoma Foundation volunteer Lourdes Rocha leads the Veterans Program and shares her experience filing claims with the VA in a recorded webinar.

Side Effects From Immune Checkpoint Inhibitors May Increase Hospitalizations, Cost for Patients With Bladder, Liver, Lung or Skin Cancer

November 4th 2021

Patients who experience side effects due to immune checkpoint inhibitors are 80% more likely to go to the emergency room and have 30% higher monthly medical costs, compared to patients who did not have side effects.

Tremelimumab Plus Imfinzi Regimen Boosts Liver Cancer Survival

October 15th 2021

Data from a phase 3 trial show that frontline tremelimumab plus Imfinzi improved overall survival in patients with liver cancer.

Liver Cancer Increasing in Rural Areas of the United States

October 15th 2021

The results, according to one of the study’s authors, indicate that liver cancer is an underrecognized and deadly cancer that is increasingly affecting people living in rural areas of the United States.

Chemo/Immunotherapy Approach Is Promising in Intermediate-Stage Liver Cancer

September 29th 2021

The new approach of chemotherapy plus Opdivo offers “the best of both treatment approaches,” says one expert.

Patients with Liver Cancer and Hepatitis or HIV May Face Higher Mortality Rates

September 24th 2021

Results from the study highlight the need to organize better screening and treatment plans for patients with liver cancer coinfected with hepatitis B, hepatitis C or HIV.

‘Landmark’ FDA Approval of Tibsovo May Improve Outcomes for Liver Cancer Subtype

September 3rd 2021

The FDA approval of Tibsovo marks the first targeted therapy for patients with this liver cancer subtype.

Tibsovo For The Treatment of Liver Cancer Subtype Receives FDA Approval

August 25th 2021

Tibsovo — which is the first targeted therapy approved for this patient population — improved survival in patients with a subtype of liver cancer.

Older Liver Cancer Survivors Are Less Informed About Life After Cancer

August 5th 2021

The results, according to the study authors, demonstrate a need to better inform older patients during treatment about survivorship after liver cancer.

Opdivo Regimen Pulled for Liver Cancer Treatment

July 28th 2021

Opdivo was granted an accelerated approval for patients with hepatocellular carcinoma, but the indication was pulled after follow-up data failed to show that the agent improved survival over another drug.

NEXT PAGE
PREVIOUS PAGE